Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies

OncoImmunology

Volumn 5, Issue 8, 2016, Pages

  Cappuzzello, Elisa ^a   Tosi, Anna ^a   Zanovello, Paola ^a,b   Sommaggio, Roberta ^a   Rosato, Antonio ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Antibody dependent cell mediated cytotoxicity (ADCC); cytokine induced killer (CIK) cells; immunotherapy; monoclonal antibodies

Indexed keywords

CD16 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; T CELL DEPLETION;

EID: 84982856618     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1199311     Document Type: Article

References (33)

1. F.Aranda, A.Buqué, N.Bloy, F.Castoldi, A.Eggermont, I.Cremer, W.H.Fridman, J.Fucikova, J.Galon, R.Spisek et al. Trial Watch:Adoptive cell transfer for oncological indications. Oncoimmunology [Internet] 2015; 4:e1046673; PMID:26451319; http://dx.doi.org/10.1080/2162402X.2015.1046673
2. S.L.Topalian, C.G.Drake, D.M.Pardoll. Perspective immune checkpoint blockade:A common denominator approach to cancer therapy. Cancer Cell [Internet] 2015; 27:450-61; PMID:25858804; http://doi.org/10.1016/j.ccell.2015.03.001
3. C.H.June, S.R.Riddell, T.N.Schumacher. Adoptive cellular therapy:A race to the finish line. Sci Transl Med [Internet] 2015; 7:280ps7-280ps7; PMID:25810311; http://dx.doi.org/10.1126/scitranslmed.aaa3643
4. S.A.Feldman, Y.Assadipour, I.Kriley, S.L.Goff, S.A.Rosenberg. Adoptive cell therapy-Tumor-Infiltrating Lymphocytes, T-Cell receptors, and chimeric antigen receptors. Semin Oncol [Internet] 2015; 42:626-39; PMID:26320066; http://dx.doi.org/10.1053/j.seminoncol.2015.05.005
5. O.Lim, M.Y.Jung, Y.K.Hwang, E.-C.Shin. Present and future of allogeneic natural killer cell therapy. Front Immunol [Internet] 2015; 6:286; PMID:26089823; http://dx.doi.org/10.3389/fimmu.2015.00286
6. D.Sangiolo. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011; 2:363-8; PMID:21716717; http://dx.doi.org/10.7150/jca.2.363
7. I.G.Schmidt-Wolf, R.S.Negrin, H.P.Kiem, K.G.Blume, I.L.Weissman. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174:139-49; PMID:1711560; http://dx.doi.org/10.1084/jem.174.1.139
8. M.Introna, M.Franceschetti, A.Ciocca, G.Borleri, E.Conti, J.Golay, A.Rambaldi. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells:an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006; 38:621-7; PMID:16980990; http://dx.doi.org/10.1038/sj.bmt.1705503
9. P.H.Lu, R.S.Negrin. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153:1687-96; PMID:7519209
10. D.Sangiolo, E.Martinuzzi, M.Todorovic, K.Vitaggio, A.Vallario, N.Jordaney, F.Carnevale-Schianca, A.Capaldi, M.Geuna, L.Casorzo et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells:Implications for their infusion across major HLA barriers. Int Immunol 2008; 20:841-8; PMID:18469328; http://dx.doi.org/10.1093/intimm/dxn042
11. M.Franceschetti, A.Pievani, G.Borleri, L.Vago, K.Fleischhauer, J.Golay, M.Introna. Cytokine-induced killer cells are terminallydifferentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009; 37:616-28; PMID:19375652; http://dx.doi.org/10.1016/j.exphem.2009.01.010
12. A.M.Jamieson, A.Diefenbach, C.W.McMahon, N.Xiong, J.R.Carlyle, D.H.Raulet. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002; 17:19-29; PMID:12150888; http://dx.doi.org/10.1016/S1074-7613(02)00333-3
13. A.Diefenbach, A.M.Jamieson, S.D.Liu, N.Shastri, D.H.Raulet. Ligands for the murine NKG2D receptor:expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1:119-26; PMID:11248803; http://dx.doi.org/10.1038/77793
14. S.Bauer, V.Groh, J.Wu, A.Steinle, J.H.Phillips, L.L.Lanier, T.Spies. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-9; PMID:10426993; http://dx.doi.org/10.1126/science.285.5428.727
15. M.R.Verneris, M.Karami, J.Baker, A.Jayaswal, R.S.Negrin. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004; 103:3065-72; PMID:15070686; http://dx.doi.org/10.1182/blood-2003-06-2125
16. M.Karimi, T.M.Cao, J.A.Baker, M.R.Verneris, L.Soares, R.S.Negrin. Silencing Human NKG2D, DAP10, and DAP12 Reduces Cytotoxicity of Activated CD8+ T Cells and NK Cells. J Immunol [Internet] 2005; 175:7819-28; PMID:16339517; http://dx.doi.org/10.4049/jimmunol.175.12.7819
17. L.C.Schmeel, F.C.Schmeel, C.Coch, I.G.H.Schmidt-Wolf. Cytokine-induced killer (CIK) cells in cancer immunotherapy:report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol [Internet] 2014; 141:839-49; PMID:25381063; http://dx.doi.org/10.1007/s00432-014-1864-3
18. A.Pievani, G.Borleri, D.Pende, L.Moretta, A.Rambaldi, J.Golay, M.Introna. Dual-functional capability of CD3 +CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011; 118:3301-10; PMID:21821703; http://dx.doi.org/10.1182/blood-2011-02-336321
19. I.G.Schmidt-Wolf, P.Lefterova, B.A.Mehta, L.P.Fernandez, D.Huhn, K.G.Blume, I.L.Weissman, R.S.Negrin. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol [Internet] 1993; 21:1673-9; PMID:7694868
20. G.D.Schmidt-Wolf, R.S.Negrin, I.G.Schmidt-Wolf. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 1997; 74:51-6; PMID:9063373; http://dx.doi.org/10.1007/s002770050257
21. G.Bonanno, P.Iudicone, A.Mariotti, A.Procoli, A.Pandolfi, D.Fioravanti, M.Corallo, A.Perillo, G.Scambia, L.Pierelli et al. Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med [Internet] 2010; 8:129; PMID:21138560; http://dx.doi.org/10.1186/1479-5876-8-129
22. S.H.Thorne, R.S.Negrin, C.H.Contag. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311:1780-4; PMID:16556847; http://dx.doi.org/10.1126/science.1121411
23. G.Trinchieri. Biology of natural killer cells. Adv Immunol [Internet] 1989; 47:187-376; PMID:2683611; http://dx.doi.org/10.1016/S0065-2776(08)60664-1
24. C.Bottino, R.Biassoni, R.Millo, L.Moretta, A.Moretta. The human natural cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering. Hum Immunol 2000; 61:1-6; PMID:10658972; http://dx.doi.org/10.1016/S0198-8859(99)00162-7
25. S.Sivori, M.Vitale, L.Morelli, L.Sanseverino, R.Augugliaro, C.Bottino, L.Moretta, A.Moretta. P46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997; 186:1129-36; PMID:9314561; http://dx.doi.org/10.1084/jem.186.7.1129
26. E.Braakman, J.van de Winkel, B.van Krimpen, M.Jansze, R.Bolhuis. CD16 on human gamma delta T lymphocytes:expression, function, and specificity for mouse IgG isotypes. Cell Immunol 1992; 143:97-107; PMID:1377991; http://dx.doi.org/10.1016/0008-8749(92)90008-D
27. H.Tokuyama, T.Hagi, S.R.Mattarollo, J.Morley, Q.Wang, H.Fai-So, F.Moriyasu, M.Nieda, A.J.Nicol. Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-Rituximab and trastuzumab. Int J Cancer [Internet] 2008; 122:2526-34; PMID:18307255; http://dx.doi.org/10.1002/ijc.23365
28. M.Sliwkowski, J.Lofgren, G.Lewis, T.Hotaling, B.Fendly, J.Fox. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26:60-70; PMID:10482195
29. J.Kurai, H.Chikumi, K.Hashimoto, K.Yamaguchi, A.Yamasaki, T.Sako, H.Touge, H.Makino, M.Takata, M.Miyata et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res [Internet] 2007; 13:1552-61; PMID:17332301; http://dx.doi.org/10.1158/1078-0432.CCR-06-1726
30. A.M.Scott, J.D.Wolchok, L.J.Old. Antibody therapy of cancer. Nat Rev Cancer [Internet] 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
31. T.Ishiyama, K.Watanabe, K.Fukuchi, K.Yajima, M.Koike, S.Tomoyasu, N.Tsuruoka. The presence of CD5low+ NK cells in normal controls and patients with pulmonary tuberculosis. Immunol Lett 1993; 37:139-44; PMID:7505001; http://dx.doi.org/10.1016/0165-2478(93)90023-U
32. C.Scheffold, M.Kornacker, Y.C.Scheffold, C.H.Contag, R.S.Negrin. Visualization of effective tumor targeting by CD8 + Natural Killer T cells redirected with bispecific antibody F(ab′)2 HER2xCD3. Cancer Res 2002; 62:5785-91; PMID:12384539
33. S.H.Yoon, J.M.Lee, S.J.Woo, M.J.Park, J.S.Park, H.S.Kim, M.Y.Park, H.J.Sohn, T.G.Kim. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR). J Clin Immunol 2009; 29:806-14; PMID:19517218; http://dx.doi.org/10.1007/s10875-009-9308-6